Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7924315 | 0.68 | CYP1A2 (0.40) | NQO2CYP2A6PIK3CBDHFRKDM4E | |
| SCHEMBL699602 | 0.67 | KCNH2 (0.38) | KDM4EALDH1A1MAPT | |
| SCHEMBL3626662 | 0.66 | — | — | |
| SCHEMBL14685902 | 0.65 | LPO (0.30) | — | |
| SCHEMBL14438041 | 0.64 | SLC9A1 (0.33) | NQO2PIK3CBDHFRKDM4EALDH1A1 | |
| SCHEMBL31036108 | 0.62 | PIK3CB (0.47) | CYP2A6PIK3CBDHFRPRKCI | |
| SCHEMBL1097841 | 0.62 | PIK3CB (0.47) | CYP2A6PIK3CBDHFRPRKCI | |
| SCHEMBL20660906 | 0.62 | SMN1; SMN2 (0.39) | CYP2A6PIK3CBDHFRKDM4EALDH1A1 | |
| SCHEMBL21530553 | 0.61 | — | — | |
| SCHEMBL7832501 | 0.61 | DYRK1A (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110997661-B | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3634958-B1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20200199113-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3634958-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-110997661-A | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2018227067-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-13 | — | — | WO | disclosed |
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2236135-A1 | STABLE PHARMACEUTICAL COMPOSITION | Asahi Kasei Pharma Corporation (JP) | 2010-10-06 | — | — | EP | disclosed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | NQO2 3984/4885CYP2A6 4381/4885PIK3CB 4503/4885 |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | NQO2 896/4885CYP2A6 720/4885PIK3CB 4802/4885 |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | NQO2 1035/4885CYP2A6 107/4885PIK3CB 4671/4885 |
| US-20200199113-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | NQO2 3984/4885CYP2A6 4381/4885PIK3CB 4503/4885 |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | NQO2, CCNI, F12 | NQO2 1/4885CYP2A6 2612/4885PIK3CB 2222/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | NQO2 1035/4885CYP2A6 107/4885PIK3CB 4671/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | NQO2 1035/4885CYP2A6 107/4885PIK3CB 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.